B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 94.44809461235216
- age_years
- 35
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.535
- G2M_CHECKPOINT+0.510
- E2F_TARGETS+0.497
- NOTCH_SIGNALING+0.480
- TGF_BETA_SIGNALING+0.462
- MYC_TARGETS_V2+0.444
- WNT_BETA_CATENIN_SIGNALING+0.395
- DNA_REPAIR+0.380
- MITOTIC_SPINDLE+0.361
- UNFOLDED_PROTEIN_RESPONSE+0.356
Top 10 suppressed
- KRAS_SIGNALING_DN-0.355
- MYOGENESIS-0.179
- INFLAMMATORY_RESPONSE-0.170
- ALLOGRAFT_REJECTION-0.159
- SPERMATOGENESIS-0.144
- INTERFERON_GAMMA_RESPONSE-0.142
- ANGIOGENESIS-0.136
- IL6_JAK_STAT3_SIGNALING-0.135
- PANCREAS_BETA_CELLS-0.115
- APICAL_SURFACE-0.107
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.919 |
| 2 | SRR934870 | — | — | 0.910 |
| 3 | BE71F250-1529-43BD-84F3-3AFE1B42D77D | — | — | 0.908 |
| 4 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.903 |
| 5 | 7779D220-647F-4D6C-890B-022208B51F57 | — | — | 0.901 |
| 6 | 431CF176-101C-482F-B2A4-617ADF6475A8 | — | — | 0.898 |
| 7 | 07D10802-F79E-495E-B842-895C444CA439 | — | — | 0.898 |
| 8 | 3DA19761-6FF3-4E8C-AA0F-C04CE2CE7037 | — | — | 0.896 |
| 9 | 8E898165-F557-4D73-9D67-ED735BE256B2 | — | — | 0.895 |
| 10 | 28B7B2FC-8270-42E3-95ED-4CC4F0979EE9 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.535 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.497 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.480 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.462 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.444 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.395 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.361 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.356 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.346 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.329 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.289 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.266 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.225 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.197 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.181 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.143 | Idelalisib | — uncovered |